| Strategic International Session2（S）(JSH) |
| Fri. November 1st 9:30 - 12:00 Room 9: Portopia Hotel Main Building Kairaku 3 |
| Novel clinical strategy utilizing noninvasive methods in patients with MASLD -the dawning era of Hepatology- | |||
| Kento Imajo | |||
| Department of Gastroenterology, Shin-Yurigaoka General Hospital | |||
|
|||
|
|||
| Background: The staging of liver fibrosis is essential for determining the prognosis in patients with metabolic dysfunction-associated (MASLD). Alternatives to liver biopsy, invasive procedure, have been investigated, such as scoring systems and imaging technique, which can be used repeatedly because of high safety. Scoring systems and biomarkers: There are several scoring systems consisting of combinations of clinical and routine laboratory parameters. FIB-4 is simple and useful for detecting severe fibrosis in patients with MASLD. Ultrasound-based elastography and MR elastography: The practical use of elastography is an epoch-making event for the staging of fibrosis in patients with MASLD. At present, several US-based elastography have been developed worldwide, most of which are covered by national health insurance in Japan. In addition, magnetic resonance elastography (MRE) became one of the most promising fields of hepatology. Latest Modalities: The latest topics include AI-based Fibro-scope, ELF score, 3D-MRE in elastography for diagnosing fibrosis, and cytokeratin 18 fragment (CK-18F) and multiparametric MRI for diagnosing liver injury, which are expected to be useful. Conclusion: Based on these principles, several clinical strategies for MASLD are recommended. To avoid redundant liver biopsies and achieve ideal monitoring, we should construct an evidence-based strategy combining scoring systems and image-based elastography for the management of patients with MASLD. We would also like to discuss approaches to liver injury as well as fibrosis. |
|||
|
Index Term 1: Noninvasive methods Index Term 2: Elastography |
|||
| Page Top | |||